US biotech PTC Therapeutics released mixed new data on its Phase II trial of PCT187 (votoplam) in Huntington’s disease. UK ...

US biotech IGM Biosciences (Nasdaq: IGMS), which is developing and delivering medicines to treat patients with autoimmune and ...

US precision oncology company Boundless Bio (Nasdaq: BOLD) has announced financial results and business highlights for the ...

A Feature on M&A, VC investment, licensing and partnerships in the radiopharmaceuticals arena.

Oculis Holding (Nasdaq: OCS) reported a net loss of $36 million for the first quarter of 2025, more than double the loss in ...

The UK government has announced a trade agreement with the USA. The UK-US Economic Prosperity Deal was agreed on Thursday May ...

The human immunodeficiency virus (HIV) market across the seven major markets (7MM: the USA, France, Germany, Italy, Spain, ...

Merck KGaA led the way in pharmaceutical M&A in April. The German company announced a $3.9 billion deal to buy the US drug ...

Switzerland-based HAYA Therapeutics, a biotech developing precision RNA-guided regulatory genome targeting therapeutics that ...

US pharma major Eli Lilly (NYSE: LLY) yesterday announced executive leadership transitions that will further enhance the ...

Genmab (Nasdaq: GMAB) posted a 19% rise in revenue to $715 million for the first quarter of 2025, driven by higher royalties ...

Positive high-level results have been presented by AstraZeneca (LSE: AZN) from the POTOMAC Phase III trial.